EIF4G1 and nephrolithiasis: By using the CRISPR-dCas13d-eIF4G platform, researchers enhanced GPX4 expression in renal epithelial cells, which reduced calcium oxalate-induced ferroptosis and kidney stone formation in both human cells and mouse models (He et al., 2024).